Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca loses landmark Losec appeal

This article was originally published in Scrip

Executive Summary

The General Court of the European Union has broadly upheld the fine imposed by the European Commission on AstraZeneca for abuse of a dominant position by blocking or delaying generic versions of its proton pump inhibitor, the anti-ulcer drug Losec (omeprazole). The move is expected to give support to the commission in its pursuit of antitrust actions against pharmaceutical companies; the industry federation EFPIA said the ruling could have a "chilling effect" on innovation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC009391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel